JP7709436B2 - 生理学的鉄過剰の処置 - Google Patents

生理学的鉄過剰の処置

Info

Publication number
JP7709436B2
JP7709436B2 JP2022531466A JP2022531466A JP7709436B2 JP 7709436 B2 JP7709436 B2 JP 7709436B2 JP 2022531466 A JP2022531466 A JP 2022531466A JP 2022531466 A JP2022531466 A JP 2022531466A JP 7709436 B2 JP7709436 B2 JP 7709436B2
Authority
JP
Japan
Prior art keywords
nori
mtp
antibody
domain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022531466A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023503513A5 (enExample
JP2023503513A (ja
Inventor
マシュー・ウェイク
フォルカー・ゲルマシェウスキー
イゴル・トイル
ジョナサン・レズリー・パップワース
デルフィーヌ・メイナール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kymab Ltd
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1917524.9A external-priority patent/GB201917524D0/en
Priority claimed from GBGB1917882.1A external-priority patent/GB201917882D0/en
Application filed by Kymab Ltd filed Critical Kymab Ltd
Publication of JP2023503513A publication Critical patent/JP2023503513A/ja
Publication of JP2023503513A5 publication Critical patent/JP2023503513A5/ja
Priority to JP2025112713A priority Critical patent/JP7862652B2/ja
Application granted granted Critical
Publication of JP7709436B2 publication Critical patent/JP7709436B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogen, Water And Hydrids (AREA)
  • Treatment Of Water By Oxidation Or Reduction (AREA)
  • Reciprocating, Oscillating Or Vibrating Motors (AREA)
JP2022531466A 2019-11-29 2020-11-27 生理学的鉄過剰の処置 Active JP7709436B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025112713A JP7862652B2 (ja) 2019-11-29 2025-07-03 生理学的鉄過剰の処置

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1917524.9 2019-11-29
GBGB1917524.9A GB201917524D0 (en) 2019-11-29 2019-11-29 Treatment for physiological iron overload
GB1917882.1 2019-12-06
GBGB1917882.1A GB201917882D0 (en) 2019-12-06 2019-12-06 Treatment for physiological iron overload
PCT/EP2020/083677 WO2021105389A1 (en) 2019-11-29 2020-11-27 Treatment for physiological iron overload

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025112713A Division JP7862652B2 (ja) 2019-11-29 2025-07-03 生理学的鉄過剰の処置

Publications (3)

Publication Number Publication Date
JP2023503513A JP2023503513A (ja) 2023-01-30
JP2023503513A5 JP2023503513A5 (enExample) 2023-12-19
JP7709436B2 true JP7709436B2 (ja) 2025-07-16

Family

ID=73698783

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022531466A Active JP7709436B2 (ja) 2019-11-29 2020-11-27 生理学的鉄過剰の処置
JP2025112713A Active JP7862652B2 (ja) 2019-11-29 2025-07-03 生理学的鉄過剰の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025112713A Active JP7862652B2 (ja) 2019-11-29 2025-07-03 生理学的鉄過剰の処置

Country Status (12)

Country Link
US (1) US12570740B2 (enExample)
EP (1) EP4065607A1 (enExample)
JP (2) JP7709436B2 (enExample)
KR (1) KR20220107252A (enExample)
CN (2) CN115380049B (enExample)
BR (1) BR112022010424A2 (enExample)
CA (1) CA3162880A1 (enExample)
CO (1) CO2022009078A2 (enExample)
IL (1) IL293314A (enExample)
MX (1) MX2022006495A (enExample)
PH (1) PH12022551299A1 (enExample)
WO (1) WO2021105389A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021251087A1 (en) * 2020-04-07 2022-12-01 Mabwell Therapeutics Inc. Anti-TMPRSS6 antibodies and uses thereof
WO2022240877A1 (en) 2021-05-11 2022-11-17 Regeneron Pharmaceuticals, Inc. Anti-tmprss6 antibodies and uses thereof
CN113667600B (zh) * 2021-07-21 2023-08-11 青岛海特生物医疗有限公司 用于二氧化碳培养箱功率分配的方法、装置及二氧化碳培养箱
WO2026019448A1 (en) * 2024-07-16 2026-01-22 Rallybio Ipe Llc Treatment of pathologies associated with beta-thalassemia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054027A1 (en) 2003-09-09 2005-03-10 Irm Llc Modulators of transmembrane protease serine 6
WO2008009895A2 (en) 2006-07-18 2008-01-24 University College Cardiff Consultants Limited Matriptase-2
JP2018529756A (ja) 2015-07-31 2018-10-11 メディミューン リミテッド ヘプシジン媒介性障害を治療するための方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
CA2672758C (en) 2006-12-18 2019-07-30 Acceleron Pharma Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
DK3241435T3 (da) 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
CN103228130B (zh) 2010-06-17 2016-03-16 科马布有限公司 动物模型及治疗分子
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
WO2016071701A1 (en) * 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
WO2016085852A1 (en) 2014-11-24 2016-06-02 Alnylam Pharmaceuticals, Inc. Tmprss6 irna compositions and methods of use thereof
CN105219780B (zh) 2015-10-30 2020-06-02 中国人民解放军第三军医大学第一附属医院 抗多亚基因型hcv抗体基因r3-19及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054027A1 (en) 2003-09-09 2005-03-10 Irm Llc Modulators of transmembrane protease serine 6
WO2008009895A2 (en) 2006-07-18 2008-01-24 University College Cardiff Consultants Limited Matriptase-2
JP2018529756A (ja) 2015-07-31 2018-10-11 メディミューン リミテッド ヘプシジン媒介性障害を治療するための方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Blood，2019年11月13日，134 (Supplement_1) : 3532，pp.1-2
Chinese Journal of Hemorheology，2014年，Vol.24, No.4，pp.472-475

Also Published As

Publication number Publication date
EP4065607A1 (en) 2022-10-05
CN115380049A (zh) 2022-11-22
CA3162880A1 (en) 2021-06-03
JP2023503513A (ja) 2023-01-30
BR112022010424A2 (pt) 2022-08-23
PH12022551299A1 (en) 2023-11-20
JP7862652B2 (ja) 2026-05-19
JP2025166832A (ja) 2025-11-06
IL293314A (en) 2022-07-01
KR20220107252A (ko) 2022-08-02
MX2022006495A (es) 2022-09-07
CO2022009078A2 (es) 2022-09-20
CN122427287A (zh) 2026-07-21
US20230025129A1 (en) 2023-01-26
US12570740B2 (en) 2026-03-10
WO2021105389A1 (en) 2021-06-03
CN115380049B (zh) 2026-03-27

Similar Documents

Publication Publication Date Title
US10385127B2 (en) Compositions and methods for antibodies targeting EPO
JP7862652B2 (ja) 生理学的鉄過剰の処置
EP2459592B1 (en) High affinity human antibodies to human angiopoietin-2
US20080102065A1 (en) Erythropoietin receptor extended duration limited agonists
US20240309100A1 (en) Anti-Trkb Monoclonal Antibodies And Methods Of Use
CN111533804A (zh) Cd47抗体及其使用方法
US20080124340A1 (en) Erythropoietin receptor agonists
CA2904337A1 (en) Chrdl-1 antigen binding proteins and methods of treatment
JP2023520969A (ja) 抗ｔｍｐｒｓｓ６抗体及びその用途
KR102871709B1 (ko) 아르테민에 대한 인간 항체 및 이의 사용 방법
EA048977B1 (ru) Лечение физиологического перенасыщения железом
BR112015011363B1 (pt) Anticorpo anti-epo, e usos do mesmo
AU2012202065A1 (en) Erythropoietin receptor extended duration limited agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250527

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250625

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250704

R150 Certificate of patent or registration of utility model

Ref document number: 7709436

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150